These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6790279)

  • 1. Immunological evidence for a proteolytic cleavage at the active site of antithrombin in the mechanism of inhibition of coagulation serine proteases.
    Wallgren P; Nordling K; Björk I
    Eur J Biochem; 1981 Jun; 116(3):493-6. PubMed ID: 6790279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The active site of antithrombin. Release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXa, factor Xa, and thrombin.
    Björk I; Jackson CM; Jörnvall H; Lavine KK; Nordling K; Salsgiver WJ
    J Biol Chem; 1982 Mar; 257(5):2406-11. PubMed ID: 6977539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of inactivation of trypsin by antithrombin.
    Danielsson A; Björk I
    Biochem J; 1982 Oct; 207(1):21-8. PubMed ID: 6817749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic evidence for insertion of the reactive-bond loop of antithrombin into the A beta-sheet of the inhibitor during trapping of target proteinases.
    Björk I; Nordling K; Olson ST
    Biochemistry; 1993 Jul; 32(26):6501-5. PubMed ID: 7687144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociation of complexes and their derivatives formed during inhibition of bovine thrombin and activated factor X by antithrombin III.
    Jesty J
    J Biol Chem; 1979 Feb; 254(4):1044-9. PubMed ID: 762113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Properties of antithrombin-thrombin complex formed in the presence and in the absence of heparin.
    Danielsson A; Björk I
    Biochem J; 1983 Aug; 213(2):345-53. PubMed ID: 6615439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of heparin and heparinlike molecules in thrombosis and atherosclerosis.
    Rosenberg RD
    Fed Proc; 1985 Feb; 44(2):404-9. PubMed ID: 3155697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formation and stability of the complex formed between human antithrombin-III and thrombin.
    Ferguson WS; Finlay TH
    Arch Biochem Biophys; 1983 Jan; 220(1):301-8. PubMed ID: 6338832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity and reactive loop length requirements for crmA inhibition of serine proteases.
    Tesch LD; Raghavendra MP; Bedsted-Faarvang T; Gettins PG; Olson ST
    Protein Sci; 2005 Feb; 14(2):533-42. PubMed ID: 15632287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator inhibitor-1.
    Wardell MR; Chang WS; Bruce D; Skinner R; Lesk AM; Carrell RW
    Biochemistry; 1997 Oct; 36(42):13133-42. PubMed ID: 9335576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routes of thrombin action in the production of proteolytically modified, secondary forms of antithrombin-thrombin complex.
    Fish WW; Orre K; Björk I
    Eur J Biochem; 1979 Nov; 101(1):39-44. PubMed ID: 510313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic peptide substrates in hemostatic testing.
    Fareed J; Messmore HL; Walenga JM; Bermes EW
    Crit Rev Clin Lab Sci; 1983; 19(2):71-134. PubMed ID: 6373139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of factor IXa inhibition by antithrombin in the presence of unfractionated and low molecular weight heparins and fucoidan.
    Mauray S; de Raucourt E; Talbot JC; Dachary-Prigent J; Jozefowicz M; Fischer AM
    Biochim Biophys Acta; 1998 Sep; 1387(1-2):184-94. PubMed ID: 9748565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and characterization of monoclonal antibodies against the human thrombin-antithrombin III complex.
    Asakura S; Yoshida N; Matsuda M; Murayama H; Soe G
    Biochim Biophys Acta; 1988 Jan; 952(1):37-47. PubMed ID: 3422029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-causing mutations in the serpin antithrombin reveal a key domain critical for inhibiting protease activities.
    Águila S; Izaguirre G; Martínez-Martínez I; Vicente V; Olson ST; Corral J
    J Biol Chem; 2017 Oct; 292(40):16513-16520. PubMed ID: 28743742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
    J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissociation of antithrombin III--thrombin complex. Formation of active and inactive antithrombin III.
    Griffith MJ; Lundblad RL
    Biochemistry; 1981 Jan; 20(1):105-10. PubMed ID: 7470462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory mechanism of serpins. Identification of steps involving the active-site serine residue of the protease.
    Stone SR; Le Bonniec BF
    J Mol Biol; 1997 Jan; 265(3):344-62. PubMed ID: 9018048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antithrombin P1 residue is important for target proteinase specificity but not for heparin activation of the serpin. Characterization of P1 antithrombin variants with altered proteinase specificity but normal heparin activation.
    Chuang YJ; Swanson R; Raja SM; Bock SC; Olson ST
    Biochemistry; 2001 Jun; 40(22):6670-9. PubMed ID: 11380262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.